YS Biopharma Co Ltd
NASDAQ:LSB

Watchlist Manager
YS Biopharma Co Ltd Logo
YS Biopharma Co Ltd
NASDAQ:LSB
Watchlist
Price: 0.627 USD -24.46%
Market Cap: $25.8m

Net Margin

-113.2%
Current
Improving
by 195.6%
vs 3-y average of -308.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-113.2%
=
Net Income
¥-100m
/
Revenue
¥615m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-113.2%
=
Net Income
$-100m
/
Revenue
¥615m

Peer Comparison

Country Company Market Cap Net
Margin
CN
YS Biopharma Co Ltd
NASDAQ:LSB
25.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
166.3B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.9B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 95% of companies in China
Percentile
5th
Based on 8 721 companies
5th percentile
-113.2%
Low
-416 945.9% — -1.5%
Typical Range
-1.5% — 8.9%
High
8.9% — 17 382.1%
Distribution Statistics
China
Min -416 945.9%
30th Percentile -1.5%
Median 3.5%
70th Percentile 8.9%
Max 17 382.1%

YS Biopharma Co Ltd
Glance View

Market Cap
25.8m USD
Industry
Biotechnology

YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.

LSB Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-113.2%
=
Net Income
¥-100m
/
Revenue
¥615m
What is YS Biopharma Co Ltd's current Net Margin?

The current Net Margin for YS Biopharma Co Ltd is -113.2%, which is above its 3-year median of -308.9%.

How has Net Margin changed over time?

Over the last 3 years, YS Biopharma Co Ltd’s Net Margin has increased from -298.3% to -113.2%. During this period, it reached a low of -545.9% on Mar 31, 2024 and a high of -118% on May 1, 2025.

Back to Top